Dr. Reddy's Laboratories Limited (BOM:500124)
India · Delayed Price · Currency is INR | Market Cap | 1.04T -6.0% |
| Revenue (ttm) | 335.93B +3.2% |
| Net Income | 42.85B -24.2% |
| EPS | 51.42 -24.1% |
| Shares Out | 832.69M |
| PE Ratio | 24.22 |
| Forward PE | 24.59 |
| Dividend | 8.00 (0.64%) |
| Ex-Dividend Date | Jul 10, 2026 |
| Volume | 399,100 |
| Open | 1,254.95 |
| Previous Close | 1,261.80 |
| Day's Range | 1,222.00 - 1,254.95 |
| 52-Week Range | 1,149.00 - 1,414.40 |
| Beta | 0.26 |
| Analysts | Hold |
| Price Target | 1,338.18 (+7.44%) |
| Earnings Date | Jul 22, 2026 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as ... [Read more]
Financial Performance
In fiscal year 2026, Dr. Reddy's Laboratories's revenue was 335.93 billion, an increase of 3.19% compared to the previous year's 325.54 billion. Earnings were 42.85 billion, a decrease of -24.22%.
Financial StatementsAnalyst Summary
According to 39 analysts, the average rating for 500124 stock is "Hold." The 12-month stock price target is ₹1,338, which is an increase of 7.44% from the latest price.
News
India's Dr Reddy's extends slide as semaglutide setback threatens first-mover edge
Dr Reddy's Laboratories slid as much as 3.7% on Friday after warning of a generic semaglutide supply disruption, raising concerns over its edge in the highly competitive diabetes market and prompting ...
Dr. Reddy's Laboratories (RDY) Faces Supply Delays Due to Quality Issues
Dr. Reddy's Laboratories (RDY) Faces Supply Delays Due to Quality Issues
India's Torrent Pharma recalls select semaglutide pens after Dr. Reddy's notice
Torrent Pharmaceuticals said on Thursday it was voluntarily recalling select batches of its Semalix semaglutide injection disposable pens after a product recall notification from its man...
Dr. Reddy's Laboratories Transcript: Investor update
A process-related impurity in scale-up batches of semaglutide API has led to a temporary supply halt, with commercial supply expected to resume by late October or early November. No recall or patient safety issues exist, but annual supply targets are reduced and some inventory may be written down.
Dr. Reddy’s Generic Ozempic Supplies Delayed on API Issue
Dr. Reddy’s Laboratories Ltd. will delay the commercial production of its generic Ozempic drug after it found an unspecified issue with the active pharmaceutical ingredient in some batches of the anti...
Dr Reddy's delays semaglutide supply due to active ingredient issue
Dr Reddy's Laboratories said on Thursday that it is delaying commercial supplies of semaglutide due to an issue related to the active pharmaceutical ingredient used in the drug, sending its shares d...
A Look at Dr Reddy's Laboratories Ltd (RDY) After 3.5% Decline -- GF Value $15.27 vs Price $14.12
A Look at Dr Reddy's Laboratories Ltd (RDY) After 3.5% Decline -- GF Value $15.27 vs Price $14.12
Stocks to watch on brokerages today, June 1: Kotak Mahindra Bank, Hitachi Energy, Dr Reddy's Laboratories, MCX and more in focus
Several domestic and global brokerage firms have released fresh reports on key Indian stocks, including Kotak Mahindra Bank, Titan, Schneider Electric, MCX, Cummins, Tata Motors Passenger Vehicles, Dr...
Stocks to watch on brokerages today, July 1: Kotak Mahindra Bank, Hitachi Energy, Dr Reddy's Laboratories, MCX and more in focus
Several domestic and global brokerage firms have released fresh reports on key Indian stocks, including Kotak Mahindra Bank, Titan, Schneider Electric, MCX, Cummins, Tata Motors Passenger Vehicles, Dr...
Dr. Reddy's Laboratories announces ₹8 per share dividend for FY 2025-26
Dr. Reddy's Laboratories has announced a final dividend of ₹8 per equity share for the financial year 2025-26. The record date for the dividend is set for Friday, July 10,…
Dr. Reddy's Laboratories releases integrated annual report for FY 2025-26
Dr. Reddy's Laboratories has published its Integrated Annual Report for the financial year 2025-26, in compliance with the Companies Act, 2013, and SEBI Listing Regulations. The report, including the ...
Dr. Reddy's Laboratories reports 50% reduction in emissions for FY2025-26
Dr. Reddy's Laboratories has released its Business Responsibility and Sustainability Report for the fiscal year 2025-26, highlighting significant achievements in various sustainability metrics. The re...
Pharma sector stocks today, June 30: Ajanta Pharma falls 2.96%, Dr. Reddy's Lab down 1.77%, Aurobindo Pharma up 1.41%
The pharma sector showed mixed movement on June 30, 2026, during morning trade. The BSE Healthcare index was up 0.15% at 49,094.24, while the broader market indices remained in negative…
Dr Reddy's Laboratories Ltd (RDY) Shares Fall 3.4% -- What GF Score of 88 Tells Investors
Dr Reddy's Laboratories Ltd (RDY) Shares Fall 3.4% -- What GF Score of 88 Tells Investors
Pharma sector stocks up today, June 29: Dr. Reddy's Lab jumps 4.11%, Indoco Remedies rises 2.63%, Strides Pharma up 2.70%
The pharmaceutical sector showed mixed movement in early trading on June 29, 2026. The S&P BSE Healthcare index rose 0.84% to 48,967.73 points, while the broader market remained nearly flat…
Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F
HYDERABAD, India--(BUSINESS WIRE)---- $RDY #AmericanDepositaryReceipts--Dr. Reddy's Laboratories Limited announces filing of Annual Report on Form 20-F.
Is It Too Late to Buy Dr Reddy's Laboratories Ltd (RDY) After 4.0% Rally? GF Value Says Undervalued
Is It Too Late to Buy Dr Reddy's Laboratories Ltd (RDY) After 4.0% Rally? GF Value Says Undervalued
Dr. Reddy's Laboratories receives seven USFDA observations at Hyderabad facility
Dr. Reddy's Laboratories has announced that the United States Food & Drug Administration (USFDA) completed a Pre-License Inspection (PLI) at its biologics manufacturing facility in Bachupally, Hyderab...
Pharma sector stocks today, June 25: Panacea Biotec rises 3.26%, Dr. Reddy's Lab up 2.01%, Orchid Pharma falls 1.70%
Pharma stocks traded with a mixed-to-positive bias on June 25, 2026, during the early morning session, with several mid-cap names posting healthy gains while a few counters slipped into the…
Pharma sector stocks today, June 24: Orchid Pharma up 3.72%, Dr. Reddys Lab gains 2.38%, Panacea Biotech falls 1.18%
Pharma stocks traded broadly in positive territory on June 24, 2026, during the early morning session, with most stocks posting modest gains. The broader market was largely flat, with the…
Pharma sector stocks rally today, June 23: IPCA Labs up 2.54%, Dr. Reddys Lab gains 2.47%, Natco Pharma rises 2.45%
Pharma stocks saw strong broad-based gains on June 23, 2026, during the early morning session, with almost all stocks trading in the green. The broader market was largely flat, with…
Dr Reddy's Laboratories Ltd (RDY) Stock Up 4.7% and Still Undervalued -- GF Score: 88/100
Dr Reddy's Laboratories Ltd (RDY) Stock Up 4.7% and Still Undervalued -- GF Score: 88/100
Bullish Two Hundred Day Moving Average Cross - RDY
In trading on Monday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed above their 200 day moving average of $13.85, changing hands as high as $14.03 per share. Dr. Reddy's Laboratories L...
Dr. Reddy's Laboratories issues 6,730 equity shares under ESOPs
Dr. Reddy's Laboratories has announced the allotment of 6,730 equity shares to eligible employees following the exercise of stock options. This allotment, which took place on 19 June 2026, is…
Dr. Reddy's Laboratories (RDY) Secures License for XACDURO Distribution
Dr. Reddy's Laboratories (RDY) Secures License for XACDURO Distribution